Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Non-Current Assets for 7 consecutive years, with $871.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 86.33% to $871.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 44.71% increase, with the full-year FY2025 number at $871.6 million, up 86.33% from a year prior.
  • Non-Current Assets was $871.6 million for Q4 2025 at Kymera Therapeutics, up from $573.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $871.6 million in Q4 2025 to a low of $69.6 million in Q2 2021.
  • A 5-year average of $280.2 million and a median of $190.1 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: crashed 52.99% in 2021, then surged 174.44% in 2024.
  • Kymera Therapeutics' Non-Current Assets stood at $154.6 million in 2021, then grew by 18.81% to $183.7 million in 2022, then dropped by 7.23% to $170.4 million in 2023, then soared by 174.44% to $467.8 million in 2024, then surged by 86.33% to $871.6 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Non-Current Assets are $871.6 million (Q4 2025), $573.7 million (Q3 2025), and $402.7 million (Q2 2025).